Biotech News
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
investors.barinthusbio.com2026-05-06 15:28 EST
Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseases Highly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third quarter of 2025 Proprietary SNAP-TI platform